Definium Therapeutics, Inc. 4

CFO Brandi Roberts received 125,000 Definium Therapeutics, Inc. common shares as a performance-based equity award that remains subject to vesting through June 2, 2028.

On September 14, 2026, Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts reported an acquisition of 125,000 common shares at a stated price of $0.00 per share, representing the third tranche of performance share units originally granted effective June 2, 2025. These performance units convert into common shares contingent on the achievement of specified clinical and regulatory milestones and remain subject to continued employment-based vesting through June 2, 2028. Following this award, Roberts beneficially owns 397,905 common shares in total, which includes 918 shares previously acquired under the company’s 2024 Employee Share Purchase Plan on August 17, 2026.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-389888

Alert Tier

5